Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.58 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.53 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.53 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.51 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.51 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.50 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.49 |
| ▸ | AGXT | P21549 | 1/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
| ▸ | ME2 | P23368 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7242758 | 0.90 | CYP2A6 (0.54) | CYP2A6ASIC3LOXL2BCL2L1RPS6KB2 | |
| SCHEMBL631264 | 0.82 | CYP2A6 (0.61) | CYP2A6ASIC3LOXL2BCL2L1RPS6KB2 | |
| SCHEMBL29534459 | 0.82 | CYP2A6 (0.61) | CYP2A6ASIC3LOXL2BCL2L1RPS6KB2 | |
| SCHEMBL12809334 | 0.81 | RPS6KB2 (0.56) | CYP2A6ASIC3LOXL2BCL2L1RPS6KB2 | |
| SCHEMBL48629 | 0.80 | CYP2A6 (0.50) | CYP2A6ASIC3LOXL2BCL2L1S1PR4 | |
| SCHEMBL1746765 | 0.79 | FFAR1 (0.60) | AKR1B1 | |
| SCHEMBL21622328 | 0.79 | SLC22A12 (0.48) | RPS6KB2SLC22A12KEAP1 | |
| SCHEMBL5266819 | 0.79 | CYP2A6 (0.45) | CYP2A6SLC22A12S1PR4S1PR5SMN1; SMN2 | |
| SCHEMBL1445507 | 0.79 | CYP2A6 (0.53) | CYP2A6ASIC3LOXL2BCL2L1AGXT | |
| SCHEMBL7433359 | 0.79 | CYP2A6 (0.53) | CYP2A6ASIC3LOXL2BCL2L1S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1354740-A | Pharmaceutical compounds | NICOX SA (FR) | 2002-06-19 | — | — | CN | claimed |
| US-11174230-B2 | (E)-4-(4-acrylamidophenoxy)-N-methylpicolinamide conjugates as potential anticancer agents | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2021-11-16 | — | — | US | disclosed |
| US-20210163413-A1 | (E)-4-(4-ACRYLAMIDOPHENOXY)-N-METHYLPICOLINAMIDE CONJUGATES AS POTENTIAL ANTICANCER AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2021-06-03 | — | — | US | disclosed |
| EP-3750886-A1 | TETRAHYDROISOQUINOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2020-12-16 | — | — | EP | disclosed |
| WO-2019154395-A1 | TETRAHYDROISOQUINOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | 中国科学院上海药物研究所 | 2019-08-15 | — | — | WO | disclosed |
| EP-1370542-B1 | BICYCLIC GUANIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF | MERCK PATENT GMBH (DE) | 2014-08-20 | — | — | EP | disclosed |
| US-7491733-B2 | useful in the treatment of pathologies associated with insulin resistance syndrome. | MERCK PATENT GMBH (DE) | 2009-02-17 | — | — | US | disclosed |
| US-20040122040-A1 | Bicyclic guanidine derivatives and therapeutic uses thereof | MERCK PATENT GMBH (DE) | 2004-06-24 | — | — | US | disclosed |
| EP-1370542-A1 | BICYCLIC GUANIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF | MERCK PATENT GmbH (DE) | 2003-12-17 | — | — | EP | disclosed |
| US-20030171413-A1 | Bicyclic heteroaromatic derivatives for the treatment of immune and inflammatory disorders | CELLTECH R & D LIMITED (GB) | 2003-09-11 | — | — | US | disclosed |
| EP-1311502-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES FOR THE TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | Celltech R&D Limited (GB) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002076963-A1 | BICYCLIC GUANIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF | MERCK PATENT GMBH (DE) | 2002-10-03 | — | — | WO | disclosed |
| CN-1354740-A | Pharmaceutical compounds | NICOX SA (FR) | 2002-06-19 | — | — | CN | disclosed |
| WO-2002016353-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES FOR THE TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | CELLTECH R & D LIMITED (GB) | 2002-02-28 | — | — | WO | disclosed |
| US-5128448-A | Peptide hormones | HOFFMAN-LA ROCHE INC. (US) | 1992-07-07 | — | — | US | disclosed |
| EP-0350163-A2 | Renin inhibitory peptides | BEECHAM GROUP PLC (GB) | 1990-01-10 | — | — | EP | disclosed |
| US-4517188-A | HYPOTENSIVE AGENTS, VASODILATORS, ADRENERGIC BETA BLOCKERS | MEAD JOHNSON & COMPANY (US) | 1985-05-14 | — | — | US | disclosed |
| EP-0068563-A2 | Heterocyclic acetic acid compounds and compositions for treating bone diseases | THE PROCTER & GAMBLE COMPANY (US) | 1983-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174230-B2 | (E)-4-(4-acrylamidophenoxy)-N-methylpicolinamide conjugates as potential anticancer agents | TUBB4A, TUBA4A, MAP4 | CYP2A6 3767/4885ASIC3 4462/4885LOXL2 4583/4885 |
| US-20040122040-A1 | Bicyclic guanidine derivatives and therapeutic uses thereof | GPR119, GCKR, GUCY1A1 | CYP2A6 2690/4885ASIC3 3065/4885LOXL2 4412/4885 |
| US-20030171413-A1 | Bicyclic heteroaromatic derivatives for the treatment of immune and inflammatory disorders | CCR1, CCR3, CCRL2 | CYP2A6 639/4885ASIC3 2838/4885LOXL2 179/4885 |
| US-20210163413-A1 | (E)-4-(4-ACRYLAMIDOPHENOXY)-N-METHYLPICOLINAMIDE CONJUGATES AS POTENTIAL ANTICANCER AGENTS | TUBB4A, TUBA4A, MAP4 | CYP2A6 3767/4885ASIC3 4462/4885LOXL2 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.